MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.54 0.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.43

Max

1.55

Põhinäitajad
By Trading Economics
Sissetulek	3.6M -34M
Müük	278K 1.9M
Kasumimarginaal	-1,786.576
Töötajad	181
EBITDA	979K -37M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+177.55% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. nov 2025

Turustatistika
By TradingEconomics
Turukapital	53M 160M
Eelmine avamishind	0.89
Eelmine sulgemishind	1.54

Uudiste sentiment

By Acuity

47%

53%

153 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. okt 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20. okt 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

20. okt 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20. okt 2025, 22:14 UTC

Market Talk

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20. okt 2025, 22:00 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20. okt 2025, 21:49 UTC

Omandamised, ülevõtmised, äriostud

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20. okt 2025, 20:56 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20. okt 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. okt 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

20. okt 2025, 20:38 UTC

Tulu

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20. okt 2025, 20:38 UTC

Tulu

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20. okt 2025, 20:38 UTC

Tulu

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20. okt 2025, 20:36 UTC

Tulu

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20. okt 2025, 20:36 UTC

Tulu

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20. okt 2025, 20:36 UTC

Tulu

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20. okt 2025, 20:36 UTC

Tulu

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20. okt 2025, 20:16 UTC

Market Talk

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20. okt 2025, 20:05 UTC

Tulu

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20. okt 2025, 19:39 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20. okt 2025, 19:34 UTC

Market Talk

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20. okt 2025, 19:32 UTC

Market Talk

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20. okt 2025, 19:00 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20. okt 2025, 18:29 UTC

Market Talk

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20. okt 2025, 18:11 UTC

Market Talk

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20. okt 2025, 18:04 UTC

Market Talk

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20. okt 2025, 17:03 UTC

Market Talk

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20. okt 2025, 17:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. okt 2025, 17:01 UTC

Market Talk

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20. okt 2025, 16:43 UTC

Market Talk

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20. okt 2025, 16:25 UTC

Market Talk

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

177.55% tõus

12 kuu keskmine prognoos

Keskmine 4.08 USD 177.55%

Kõrge 7 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

153 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.